Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.

Jerald SadoffGlenda E GrayAn VandeboschVicky CárdenasGeorgi ShukarevBeatriz GrinsztejnPaul A GoepfertCarla TruyersIlse Van DrommeBart SpiessensJohan VingerhoetsJerome CustersGert ScheperMerlin L RobbJohn TreanorMartin F RyserDan H BarouchEdith SwannMary A MarovichKathleen M NeuzilLawrence CoreyJeffrey StoddardKarin HardtJavier Ruiz-GuiñazúMathieu Le GarsHanneke SchuitemakerJohan Van HoofFrank StruyfMacaya Douoguihnull null

Published in: The New England journal of medicine (2022)

A single dose of Ad26.COV2.S provided 52.9% protection against moderate to severe-critical Covid-19. Protection varied according to variant; higher protection was observed against severe Covid-19, medical intervention, and death than against other end points and lasted for 6 months or longer. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.).

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
early onset
randomized controlled trial
healthcare
high intensity
drug induced
machine learning
deep learning
neural network